Validation of interobserver agreement in lung cancer assessment: Hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: The 2004 world health organization classification and therapeutically relevant subsets

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 1, 2013, Pages 32-40

  Grilley Olson, Juneko E ^a,b   Hayes, D Neil ^a,b   Moore, Dominic T ^b   Leslie, Kevin O ^b   Wilkerson, Matthew D ^b   Qaqish, Bahjat F ^b   Hayward, Michele C ^b   Cabanski, Christopher R ^b,d   Yin, Xiaoying ^b   Socinski, Mark A ^e   Stinchcombe, Thomas E ^a,b   Thorne, Leigh B ^c   Allen, Timothy Craig ^f   Banks, Peter M ^g   Beasley, Mary B ^h   Borczuk, Alain C ⁱ   Cagle, Philip T ^k   Christensen, Rebecca ^l   Colby, Thomas V ^b   Deblois, Georgean G ^m   Elmberger, Göran ⁿ   Graziano, Paolo ^o   Hart, Craig F ^p   Jones, Kirk D ^q   Maia, Diane M ^p   Miller, C Ryan ^j   Nance, Keith V ^p   Travis, William D ^r   Funkhouser, William K ^b,c   more..

^a Division of Hematology Oncology   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d MAYO CLINIC   (United States)

^e University of North Carolina at Chapel Hill   (United States)

^f UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS AT TYLER   (United States)

^h CAROLINAS MEDICAL CENTER   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j NewYork Presbyterian Hospital   (United States)

^k HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^l Norton Healthcare   (United States)

^m Karolinska University Hospital ^*  (United States)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^o SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^p Rex Healthcare ^*  (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EOSIN; HEMATOXYLIN;

ARTICLE; CLASSIFICATION; FEMALE; HUMAN; INFORMATION PROCESSING; INTERNET; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; OBSERVER VARIATION; PATHOLOGY; STAINING; VALIDATION STUDY; WORLD HEALTH ORGANIZATION;

CARCINOMA, NON-SMALL-CELL LUNG; DATA COLLECTION; EOSINE YELLOWISH-(YS); FEMALE; HEMATOXYLIN; HUMANS; INTERNET; LUNG NEOPLASMS; MALE; OBSERVER VARIATION; PATHOLOGY, SURGICAL; STAINING AND LABELING; WORLD HEALTH ORGANIZATION;

EID: 84872047310     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0033-OA     Document Type: Article

References (38)

1. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184-2191.
2. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26(21):3543-3551.
3. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: A literature review. J Thorac Oncol. 2008;3(12):1468-1481.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
5. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958-967.
6. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23(4):857-865.
7. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart. 3rd ed. Lyon, France: IARC Press; 2004. World Health Organization Classification of Tumours; vol 10.
8. Kreyberg L, Liebow AA, Uehlinger EA. Histological Typing of Lung Tumours. 1st ed. Geneva, Switzerland: World Health Organization; 1967. International Histological Classification of Tumours; no. 1.
9. The World Health Organization histological typing of lung tumours: Second edition. Am J Clin Pathol. 1982;77(2):123-136.
10. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, Sobin LH. Histological Typing of Lung and Pleural Tumours. 3rd ed. Berlin, Germany: Springer-Verlag; 1999. World Health Organization International Histological Classification of Tumours.
11. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174.
12. Burnett RA, Howatson SR, Lang S, et al. Observer variability in histopathological reporting of non-small cell lung carcinoma on bronchial biopsy specimens. J Clin Pathol. 1996;49(2):130-133.
13. Burnett RA, Swanson Beck J, Howatson SR, et al. Observer variability in histopathological reporting of malignant bronchial biopsy specimens. J Clin Pathol. 1994;47(8):711-713.
14. Butler C, Samet JM, Humble CG, Sweeney ES. Histopathology of lung cancer in New Mexico, 1970-72 and 1980-81. J Natl Cancer Inst. 1987;78(1): 85-90.
15. Campobasso O, Andrion A, Ribotta M, Ronco G. The value of the 1981 WHO histological classification in inter-observer reproducibility and changing pattern of lung cancer. Int J Cancer. 1993;53(2):205-208.
16. Colby TV, Tazelaar HD, Travis WD, Bergstralh EJ, Jett Jr. Pathologic review of the Mayo Lung Project cancers [corrected]: Is there a case for misdiagnosis or overdiagnosis of lung carcinoma in the screened group? Cancer. 2002;95(11):2361-2365.
17. Feinstein AR, Gelfman NA, Yesner R. Observer variability in the histopathologic diagnosis of lung cancer. Am Rev Respir Dis. 1970;101(5):671-684.
18. Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst. 2004;96(14):1105-1107.
19. Ghandur-Mnaymneh L, Raub WA Jr, Sridhar KS, Albores-Saavedra J, Gould E, Duncan RC. The accuracy of the histological classification of lung carcinoma and its reproducibility: A study of 75 archival cases of adenosquamous carcinoma. Cancer Invest. 1993;11(6):641-651.
20. Hanai A, Whittaker JS, Tateishi R, Sobin LH, Benn RT, Muir CS. Concordance of histological classification of lung cancer with special reference to adenocarcinoma in Osaka, Japan, and the North-West Region of England. Int J Cancer. 1987;39(1):6-9.
21. Kreuzer M, Muller KM, Brachner A, et al. Histopathologic findings of lung carcinoma in German uranium miners. Cancer. 2000;89(12):2613-2621.
22. Sorensen JB, Hirsch FR, Gazdar A, Olsen JE. Interobserver variability in histopathologic subtyping and grading of pulmonary adenocarcinoma. Cancer. 1993;71(10):2971-2976.
23. Stang A, Pohlabeln H, Muller KM, Jahn I, Giersiepen K, Jockel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.
24. Yamamoto S, Sobue T, Yamaguchi N, et al. Reproducibility of diagnosis and its influence on the distribution of lung cancer by histologic type in Osaka, Japan. Jpn J Cancer Res. 2000;91(1):1-8.
25. Altman DG. Practical Statistics for Medical Research. Boca Raton, FL: Chapman & Hall/CRC; 1991.
26. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37-46.
27. Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull. 1971;76(5):378-382.
28. Liu RY, Singh K. Using I.I.D. bootstrap inference for general non-i.i.d. models. J Stat Plan Infer. 1995;43(1-2):67-75.
29. DasGupta A. SpringerLink: Asymptotic Theory of Statistics and Probability. New York, NY: Springer; 2008. Springer Texts in Statistics.
30. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29-36.
31. R Development Core Team. R: A Language and Environment for Statistical Computing. [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2008.
32. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542- 2550.
33. Sarkaria IS, Zakowski MF, Pham D, et al. Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components. Ann Thorac Surg. 2008;85(1):216-223.
34. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247-4253.
35. The Cancer Genome Atlas Research Network, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
36. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-285.
37. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet. 2009; 374(9699):1432-1440.
38. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies. Oncologist. 2009;14(3):253-263.